MyFinsight
Home
Blog
About
Contact
2031 and thereafter
$23,392K
2030
$8,061K
2028
$8,061K
2027
$8,061K
2027-Cost Of Sales
$7,994K
2026 (remainder of
year)
$6,045K
2027-Selling General And
Administrative Expenses
$67K
Cash and cash
equivalents
$4,791,676K
Accounts receivable, net
$938,019K
Inventories, net
$681,590K
Prepaid expenses and
other current assets
$189,995K
Property, plant and
equipment, net
$1,640,918K
Operating lease
right-of-use assets
$145,497K
Other non-current
assets
$104,243K
Intangible assets, net
$61,681K
Total current assets
$6,601,280K
Total non-current
assets
$1,952,339K
Total assets
$8,553,619K
Total liabilities and
shareholders equity
$8,553,619K
Total shareholders
equity
$4,760,442K
Total liabilities
$3,793,177K
Accumulated deficit
-$8,092,546K
Accumulated other
comprehensive loss
-$53,482K
Additional paid-in capital
$12,906,326K
Total non-current
liabilities
$1,981,667K
Total current
liabilities
$1,811,510K
Ordinary shares, 0.0001
par value per share...
$144K
Long-term debt
$962,515K
Sale of future
royalty liability,...
$831,664K
Other long-term
liabilities
$81,952K
Deferred tax liabilities
$55,866K
Operating lease
liabilities, non-current...
$49,670K
Accrued expenses and
other payables
$1,079,283K
Accounts payable
$423,546K
Short-term debt
$116,140K
Sale of future
royalty liability,...
$72,735K
Tax payable
$63,522K
Research and development
cost share...
$35,700K
Operating lease
liabilities, current portion
$20,584K
Back
Back
Balance Sheet
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)
source: myfinsight.com